View All Items

Title: A method of verification of the total treatment time for the APBI (Accelerated Partial Breast Irradiation) devices: CONTURA Multilumen Balloon and SAVI Applicator.
Creator: Kyriacou, Andreas, Charles E. Schmidt College of Science, Department of Physics
Abstract/Description: A simple method to verify the total treatment time generated by the treatment planning system (TPS) when the CONTURA MLB or the SAVI applicator are used for APBI treatments has been developed. The method compares the time generated by the TPS to a predicted time, calculated by inserting parameters obtained from the TPS in equations generated in this Thesis. The equations were generated by linearly fitting data from clinical cases that had been treated using the Contura MLB or the SAVI...
Show moreA simple method to verify the total treatment time generated by the treatment planning system (TPS) when the CONTURA MLB or the SAVI applicator are used for APBI treatments has been developed. The method compares the time generated by the TPS to a predicted time, calculated by inserting parameters obtained from the TPS in equations generated in this Thesis. The equations were generated by linearly fitting data from clinical cases that had been treated using the Contura MLB or the SAVI applicator at the Lynn Cancer Institute of the Boca Raton Regional Hospital. The parameters used were the PTV coverage, Air Kerma Strength, Balloon Volume (Contura data fit) and Evaluation PTV (SAVI data fit). As an outcome of this research, it is recommended that the plan should be reevaluated when the percent difference between the generated and the predicted times exceeds 5% for the Contura MLB, or 10% for the SAVI.
Show less
Date Issued: 2011
PURL: http://purl.flvc.org/FAU/3332254
Subject Headings: Cancer, Radiotherapy, Breast, Cancer, Radiotherapy, Breast, Cancer, Treatment
Format: Document (PDF)

Title: Evaluation of surface dose outside the treatment area for breast cancer irradiation modalities using thermoluminescence dosimeters (TLDs).
Creator: Khanal, Suraj P., Ouhib, Zoubir, Leventouri, Theodora, Graduate College
Date Issued: 2013-04-12
PURL: http://purl.flvc.org/fcla/dt/3361319
Subject Headings: Thermoluminescence dosimetry, Breast--Cancer--Treatment
Format: Document (PDF)

Title: THE TRIFECTA: A NOVEL COMBINATORIAL THERAPY SPARES IMMUNE CELLS WHILE INDUCING IMMUNOGENIC CELL DEATH IN HUMAN MAMMARY ADENOCARCINOMA AND MOUSE MAMMARY CARCINOMA.
Creator: Motii, Youssef, Hartmann, James X., Florida Atlantic University, Department of Biological Sciences, Charles E. Schmidt College of Science
Abstract/Description: According to U.S. Breast Cancer Statistics, about 1 in 8 U.S. women will develop invasive breast cancer during their lifetime. Chemotherapeutics that are used on patients currently often lead to tumor resistance, bone marrow suppression and cachexia. This study evaluated a novel combination of three non-mutagenic compounds for their effectiveness against mammary tumor cells, toxicity towards immune cells, ability to provoke the expression of immunogenic cell death (ICD) markers, and killing...
Show moreAccording to U.S. Breast Cancer Statistics, about 1 in 8 U.S. women will develop invasive breast cancer during their lifetime. Chemotherapeutics that are used on patients currently often lead to tumor resistance, bone marrow suppression and cachexia. This study evaluated a novel combination of three non-mutagenic compounds for their effectiveness against mammary tumor cells, toxicity towards immune cells, ability to provoke the expression of immunogenic cell death (ICD) markers, and killing in 3D tumor models. Methotrexate (MTX), 2-deoxyglucose (2DG), and wogonin (WGN) were combined at doses well below their EC50 values yet effectively killed human and mouse breast cancer cells. The combination inhibited cancer cell colony formation and induced a high degree of cell death in multiple malignant tumor cell lines. Importantly, the combination did not significantly inhibit the viability of peripheral-blood mononuclear cells (PBMCs), even when employed at 3X the concentration that killed cancer cells. In marked contrast, low-dose doxorubicin, a common therapeutic for breast cancers, significantly decreased PBMC viability and increased the percentage of cell death. Our novel combinatorial therapy (Trifecta) elicited the significant expression of three ICD hallmarks: calreticulin surface expression, ATP secretion, and HMGB-1 release. In all cases, Trifecta elicited an equal or greater degree of ICD-marker expression compared to doxorubicin, a known inducer of ICD. We show significant efficacy of Trifecta against human and mouse mammary 3D tumor models grown in Matrigel® ECM-complex containing culture medium, and reaffirm the marked resistance of tumorspheres towards the conventional chemotherapeutic doxorubicin. The effectiveness of Trifecta in an acceptable surrogate model for mouse studies bodes well for translation of our findings to the clinic. In conclusion, Trifecta has proven highly effective against tumor cells grown either as monolayers or tumorspheres, without significant cytotoxic effects towards proliferating immune cells. Furthermore, treatment with this combination elicits ICD, which has the potential to prime an adaptive immune response against tumor cells and prevent future relapse. The drugs chosen for our combination target metabolic pathways that cancer cells are heavily dependent upon and do not interact with or induce mutations in DNA. These properties place Trifecta at the forefront of developing anticancer therapies.
Show less
Date Issued: 2020
PURL: http://purl.flvc.org/fau/fd/FA00013606
Subject Headings: Cancer--Treatment, Breast--Cancer, Methotrexate, Deoxyglucose, wogonin
Format: Document (PDF)

Title: Variations of Pericardial Dose at Different Respiratory Status in Accelerated Partial Breast Irradiation (APBI) Using Cyberknife M6™ Multileaf Collimators (CKMLC).
Creator: Long, Samanthia C., Shang, Charles, Leventouri, Theodora, Florida Atlantic University, Charles E. Schmidt College of Science, Department of Physics
Abstract/Description: The purpose of this study is to investigate the changes of the pericardial dose at different respiratory phases and statuses in accelerated partial breast irradiation (APBI) using Cyberknife M6™ multileaf collimators (CK-MLC). Anonymous 6 female patient files with respiration gated four-dimensional computed tomography (4DCT) sets, and 6 left breast cancer cases with CT images in free-breathing (FB) and deep inhalation breath-hold (BH) were selected. One CT image set from each patient was...
Show moreThe purpose of this study is to investigate the changes of the pericardial dose at different respiratory phases and statuses in accelerated partial breast irradiation (APBI) using Cyberknife M6™ multileaf collimators (CK-MLC). Anonymous 6 female patient files with respiration gated four-dimensional computed tomography (4DCT) sets, and 6 left breast cancer cases with CT images in free-breathing (FB) and deep inhalation breath-hold (BH) were selected. One CT image set from each patient was planned for APBI in Accuray Multiplan™ 5.2, and respectively compared its pericardial dose with those from CT sets of other respiratory phases. All the comparable CT images were fused in the planning system according to the left chest wall, among which the lung gap anterior to the pericardium varies by the lung expansion. For the purpose of this study, the tumor volume was outlined in the media-lower quadrant of the left breast where this lung gap is relatively small. All the plans in this study met the requirements set by the National Surgical Adjuvant Breast and Bowel Project/Radiation Therapy Oncology Group (NSABP/RTOG), specifically protocol B-39/RTOG 0413. From the comparisons in this investigation, the mean relative pericardial dose of the BH CT group showed significant or 45% (p < 0.01) lower value than that of FB CT group. However, in FB 4DCT group, 3 of 6 cases indicated a meaningful reduction (p < 0.05) in 100% inhalation phase when compared with the mean dose over other phases. The inconsistent pericardial doses were displayed in FB 4DCT group due to minimal changes in the anterior lung gap of the pericardium, when the diaphragmatic breathing was dominant in those patients.
Show less
Date Issued: 2015
PURL: http://purl.flvc.org/fau/fd/FA00004518, http://purl.flvc.org/fau/fd/FA00004518
Subject Headings: Breast--Cancer--Radiotherapy., Breast--Cancer--Treatment., Radiation--Measurement--Methodology., Medical physics.
Format: Document (PDF)

Title: Efficacy of Combining 3-Bromopyruvate with Fenofibrate in Killing the Human Breast Cancer Cell Line MCF-7.
Creator: Graham, Rashean A., Hartmann, James X., Florida Atlantic University, Department of Biological Sciences, Charles E. Schmidt College of Science
Abstract/Description: The goal of our research was to find a cancer treatment that was both effective and cancer specific, sparing immune and normal tissues. We evaluated the efficacy of a combinatorial treatment using the glycolytic inhibitor 3-bromopyruvate and the fatty acid metabolism inhibitor fenofibrate in cancer, immune and normal tissue cells lines. Treatment of the human breast cancer MCF-7 with 3-bromopyruvate and fenofibrate resulted in increased cell death and decreased colony formation. In the immune...
Show moreThe goal of our research was to find a cancer treatment that was both effective and cancer specific, sparing immune and normal tissues. We evaluated the efficacy of a combinatorial treatment using the glycolytic inhibitor 3-bromopyruvate and the fatty acid metabolism inhibitor fenofibrate in cancer, immune and normal tissue cells lines. Treatment of the human breast cancer MCF-7 with 3-bromopyruvate and fenofibrate resulted in increased cell death and decreased colony formation. In the immune cells known as peripheral blood mononuclear cells our combinatorial treatment displayed less toxicity than the traditional chemotherapy doxorubicin. Our combinatorial treatment displayed greater toxicity than doxorubicin towards an established breast cell line MCF- 10A, described in the literature as representing normal breast cells. We have shown for the first time a synergistic relationship between 3-bromopyruvate and fenofibrate.
Show less
Date Issued: 2020
PURL: http://purl.flvc.org/fau/fd/FA00013556
Subject Headings: Breast--Cancer--Treatment, bromopyruvate, Fenofibrate, MCF-7 Cells
Format: Document (PDF)

Title: Anticarcinogenic effects of genistein and anthocyanin extract in MCF-7 human breast cancer cells.
Creator: Stinson, Corine M., Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description: This study investigated potential apoptotic and anti-proliferative effects of the phytochemicals, genistein and anthocyanin extract, as single and combined treatments in MCF-7 human breast cancer cells. Cells were exposed to single and combined treatments with the phytochemiclas for 48 and 72 hours. Cell viability was assessed using the MTT bioassay. Apoptosis induction was assessed using acridine orange ethidium bromide and rhodamine 123 ethidium bromide fluorescence assays. Both singe and...
Show moreThis study investigated potential apoptotic and anti-proliferative effects of the phytochemicals, genistein and anthocyanin extract, as single and combined treatments in MCF-7 human breast cancer cells. Cells were exposed to single and combined treatments with the phytochemiclas for 48 and 72 hours. Cell viability was assessed using the MTT bioassay. Apoptosis induction was assessed using acridine orange ethidium bromide and rhodamine 123 ethidium bromide fluorescence assays. Both singe and combination treatments induced dose- and time-dependent apoptotic cell death in MCF-7 cells. The percentage of apoptosis was higher in combination treatments than single treatments with either phytochemical, although the difference was not statistically significant. The combination of genistein and anthocyanin extract peaked in efficacy at 48 hours of treatment, to exhibit significantly greater (P<. O5) dose- and time-dependent cell cytotoxicity than single treatments. This study reveals potential chemopreventive implications for the complementary effects of genistein and anthocyanin extract.
Show less
Date Issued: 2011
PURL: http://purl.flvc.org/FAU/3320108
Subject Headings: Phytochemicals, Therapeutic use, Phytoestrogens, Physiological effect, Breast, Cancer, Risk factors, Breast, Cancer, Treatment, Probiotics, Cancer, Chemoprevention, Antioxidants, Therapeutic use
Format: Document (PDF)

Title: Effects of gene selection and data sampling on prediction of breast cancer treatments.
Creator: Heredia, Brian, Khoshgoftaar, Taghi M., Florida Atlantic University, College of Engineering and Computer Science, Department of Computer and Electrical Engineering and Computer Science
Abstract/Description: In recent years more and more researchers have begun to use data mining and machine learning tools to analyze gene microarray data. In this thesis we have collected a selection of datasets revolving around prediction of patient response in the specific area of breast cancer treatment. The datasets collected in this paper are all obtained from gene chips, which have become the industry standard in measurement of gene expression. In this thesis we will discuss the methods and procedures used in...
Show moreIn recent years more and more researchers have begun to use data mining and machine learning tools to analyze gene microarray data. In this thesis we have collected a selection of datasets revolving around prediction of patient response in the specific area of breast cancer treatment. The datasets collected in this paper are all obtained from gene chips, which have become the industry standard in measurement of gene expression. In this thesis we will discuss the methods and procedures used in the studies to analyze the datasets and their effects on treatment prediction with a particular interest in the selection of genes for predicting patient response. We will also analyze the datasets on our own in a uniform manner to determine the validity of these datasets in terms of learning potential and provide strategies for future work which explore how to best identify gene signatures.
Show less
Date Issued: 2014
PURL: http://purl.flvc.org/fau/fd/FA00004292, http://purl.flvc.org/fau/fd/FA00004292
Subject Headings: Antineoplastic agents -- Development, Breast -- Cancer -- Treatment, Cancer -- Genetic aspects, DNA mircroarrays, Estimation theory, Gene expression
Format: Document (PDF)

Title: A Study on Reversing the Immunosuppressive Phenotype of Tumor Associated Macrophages.
Creator: Liddle, Genevieve M., Hartmann, James X., Florida Atlantic University, Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description: Extracellular stimuli may influence the M1/M2 phenotypic polarization of macrophages. We examined M1/M2 biomarkers, phagocytic activity, and tumoricidal activity in RAW 264.7 mouse macrophages. Macrophages were treated with conditioned media (CM) from 4T1 breast cancer cells, curcumin, 22-oxacalcitriol, LPS, or a combination of the previously listed. Arginase activity, a M2 phenotypic biomarker, was upregulated by the treatment of macrophages with conditioned media. Curcumin, 22-...
Show moreExtracellular stimuli may influence the M1/M2 phenotypic polarization of macrophages. We examined M1/M2 biomarkers, phagocytic activity, and tumoricidal activity in RAW 264.7 mouse macrophages. Macrophages were treated with conditioned media (CM) from 4T1 breast cancer cells, curcumin, 22-oxacalcitriol, LPS, or a combination of the previously listed. Arginase activity, a M2 phenotypic biomarker, was upregulated by the treatment of macrophages with conditioned media. Curcumin, 22- oxacalcitriol, and LPS partially inhibited RAW 264.7 arginase activity in the presence of 4T1 breast cancer media. 22-oxacalcitriol increased the phagocytic ability of RAW 264.7 macrophages in the presence of M2 polarizing substances produced by the 4T1 breast cancer cells. Also, LPS increased RAW 264.7 phagocytic ability in the presence of 4T1 breast cancer CM. This study looked at the potential substances that would possibly reverse the M2 tumor promoting macrophage phenotype seen in the breast cancer tumor environment.
Show less
Date Issued: 2017
PURL: http://purl.flvc.org/fau/fd/FA00004867
Subject Headings: Macrophages., Breast--Cancer--Treatment., Tumors--Immunological aspects., Cancer--Immunological aspects., Biological response modifiers., Cancer--Molecular aspects.
Format: Document (PDF)

Title: Therapeutic potential of pomegranate and genistein for human breast cancer.
Creator: Louis Jeune, Marie Adeline, Florida Atlantic University, Kumi-Diaka, James
Abstract/Description: The therapeutic potential of pomegranate and genistein on growth inhibition of human breast cancer cells was investigated. Methods. Cells (MCF-7) were initially cultured for 48 hr to achieve 80% confluence; and then exposed to the agents in single and combination treatments. Post-treatment analysis was done by using a series of bioassays, including LDH, MTS, AcrO-EthBr, Annexin-FITC and TUNEL assays for growth inhibition and apoptosis detection; and Caspase-3 and NQO1 for molecular pathways...
Show moreThe therapeutic potential of pomegranate and genistein on growth inhibition of human breast cancer cells was investigated. Methods. Cells (MCF-7) were initially cultured for 48 hr to achieve 80% confluence; and then exposed to the agents in single and combination treatments. Post-treatment analysis was done by using a series of bioassays, including LDH, MTS, AcrO-EthBr, Annexin-FITC and TUNEL assays for growth inhibition and apoptosis detection; and Caspase-3 and NQO1 for molecular pathways of apoptosis. Results. Pomegranate and genistein showed significant dose- and time-dependent cytotoxic and growth inhibition effects as well as apoptosis induction in MCF-7 cancer cells, with significantly higher ( P < 0.01) effects in the combination treatments than in the single treatments. Both drugs induced apoptosis through a caspase-mediated mechanism and independent of NQO1. Discussion and conclusions. Pomegranate and genistein inhibit the growth of MCF-7 breast cancer cells through induction of apoptosis with combination treatment being more efficacious than single treatments.
Show less
Date Issued: 2004
PURL: http://purl.flvc.org/fcla/dt/13130
Subject Headings: Phytochemicals--Physiological effect, Breast--Cancer--Molecular aspects, Women--Diseases--Alternative treatment, Apoptosis--Molecular aspects, Breast--Cancer--Treatment
Format: Document (PDF)

Title: Genistein targets only proliferating but not quiescent cells: Potential therapeutic significance in breast cancer.
Creator: Bodepudi, Sreedevi., Florida Atlantic University, Kumi-Diaka, James
Abstract/Description: Phytochemicals are biologically active secondary plant metabolites that could mimic biological activities. In this study genistein isoflavone, a phytochemical present in soy was investigated to determine its effect on the growth of human breast cancer cell line GI-101 and normal breast epithelial cells in vitro. The cells were exposed to varying concentrations of genistein isoflavone for 24 and 48 hour time periods and the effect was determined using post-treatment assays: MTT and Trypan Blue...
Show morePhytochemicals are biologically active secondary plant metabolites that could mimic biological activities. In this study genistein isoflavone, a phytochemical present in soy was investigated to determine its effect on the growth of human breast cancer cell line GI-101 and normal breast epithelial cells in vitro. The cells were exposed to varying concentrations of genistein isoflavone for 24 and 48 hour time periods and the effect was determined using post-treatment assays: MTT and Trypan Blue for cell viability; LDH assay for cytotoxicity; Rhodamine 123/Propidium Iodide and Ethidium Bromide/Acridine Orange assays for treatment-induced apoptosis and FAM Poly caspase assay for mechanism of action. The overall results revealed that genistein inhibited cell growth and proliferation through apoptosis in the cells in both time and dose-dependent manner. Normal breast epithelial cells were not significantly affected by genistein at the corresponding dosages. Based on the results obtained, it was concluded that genistein isoflavone could offer therapeutic efficacy in human breast carcinoma without significantly affecting the normal breast epithelial cells.
Show less
Date Issued: 2006
PURL: http://purl.flvc.org/fcla/dt/13315
Subject Headings: Phytochemicals--Physiological effect, Breast--Cancer--Molecular aspects, Women--Diseases--Alternative treatment, Breast--Cancer--Treatment, Apoptosis--Molecular aspects
Format: Document (PDF)

Title: A Dosimetric Comparison of 3D-CRT, IMRT, and SAVI HDR via NTCP/TCP and DVH Analysis of Critical Organs for Breast Cancer.
Creator: Wisnoskie, Sarah, Pella, Silvia, Florida Atlantic University, Charles E. Schmidt College of Science, Department of Physics
Abstract/Description: Accelerated Partial Breast Irradiation (APBI) is a common treatment of breast cancer with many modalities including 3D Conformal Radiation Therapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT), and High Dose Rate Brachytherapy (HDR). In this research, a retrospective analysis of patient’s data was performed to analyze the NTCP/TCP (Normal Tissue Complication Probability/Tumor Control Probability) and Dose Volume Histogram (DVH) parameters for HDR with SAVI, 3D, and IMRT and compare...
Show moreAccelerated Partial Breast Irradiation (APBI) is a common treatment of breast cancer with many modalities including 3D Conformal Radiation Therapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT), and High Dose Rate Brachytherapy (HDR). In this research, a retrospective analysis of patient’s data was performed to analyze the NTCP/TCP (Normal Tissue Complication Probability/Tumor Control Probability) and Dose Volume Histogram (DVH) parameters for HDR with SAVI, 3D, and IMRT and compare them focusing on critical organs such as the heart, ipsilateral lung, chest wall, ribs, and skin. TCP was 90.275%, 55.948%, and 53.369% for HDR, 3D, and IMRT respectively. The ribs were the most sensitive critical organ for all 3 modalities with a mean NTCP of 8%, 15%, and 8% for HDR, 3D, and IMRT respectively. DVH analysis showed HDR spares critical organs more than EBRT except for 2 patients receiving high doses to the ribs and chest wall.
Show less
Date Issued: 2019
PURL: http://purl.flvc.org/fau/fd/FA00013281
Subject Headings: Radiation dosimetry--Evaluation, Breast--Cancer--Treatment, Organs, Tissues--Effect of radiation on
Format: Document (PDF)

Title: Dosimetric and Radiobiological Comparison of Forward Tangent Intensity Modulated Radiation Therapy (FT-IMRT) and Volumetric Modulated Arc Therapy (VMAT) for Early Stage Whole Breast Cancer.
Creator: Moshiri Sedeh, Nader, Pella, Silvia, Leventouri, Theodora, Florida Atlantic University, Charles E. Schmidt College of Science, Department of Physics
Abstract/Description: Intensity Modulated Radiation Therapy (IMRT) is a well-known type of external beam radiation therapy. The advancement in technology has had an inevitable influence in radiation oncology as well that has led to a newer and faster dose delivery technique called Volumetric Modulated Arc Therapy (VMAT). Since the presence of the VMAT modality in clinics in the late 2000, there have been many studies in order to compare the results of the VMAT modality with the current popular modality IMRT for...
Show moreIntensity Modulated Radiation Therapy (IMRT) is a well-known type of external beam radiation therapy. The advancement in technology has had an inevitable influence in radiation oncology as well that has led to a newer and faster dose delivery technique called Volumetric Modulated Arc Therapy (VMAT). Since the presence of the VMAT modality in clinics in the late 2000, there have been many studies in order to compare the results of the VMAT modality with the current popular modality IMRT for various tumor sites in the body such as brain, prostate, head and neck, cervix and anal carcinoma. This is the first study to compare VMAT with IMRT for breast cancer. The results show that the RapidArc technique in Eclipse version 11 does not improve all aspects of the treatment plans for the breast cases automatically and easily, but it needs to be manipulated by extra techniques to create acceptable plans thus further research is needed.
Show less
Date Issued: 2015
PURL: http://purl.flvc.org/fau/fd/FA00004526, http://purl.flvc.org/fau/fd/FA00004526
Subject Headings: Breast -- Cancer -- Treatment, Cancer -- Radiation therapy, Image guided radiation therapy, Radiation dosimetry, Radiotherapy -- Technological innovations
Format: Document (PDF)

Title: The Impact of Pharmacological Targeting of Abnormal Tumor Metabolism with 3-Bromopyruvate on Dendritic Cell Mediated Tumoral Immunity.
Creator: Lang, Kevin, Hartmann, James X., Florida Atlantic University, Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description: Studies have shown that tumor cells are susceptible to pharmacological targeting of their altered glycolytic metabolism with a variety of compounds that result in apoptosis. One such compound, 3-bromopyruvate (3-BP), has been shown to eradicate cancer in an animal model. However, no studies have shown whether the apoptotic fragments resulting from 3-BP treatment have the capacity to elicit an immunogenic cell death that activates dendritic cells, the primary antigen presenting cell in the...
Show moreStudies have shown that tumor cells are susceptible to pharmacological targeting of their altered glycolytic metabolism with a variety of compounds that result in apoptosis. One such compound, 3-bromopyruvate (3-BP), has been shown to eradicate cancer in an animal model. However, no studies have shown whether the apoptotic fragments resulting from 3-BP treatment have the capacity to elicit an immunogenic cell death that activates dendritic cells, the primary antigen presenting cell in the immune system. Immunogenic cell death is critical to eliciting an effective adaptive immune response that selectively kills additional target cells and generates immunological memory. We demonstrated that 3-bromopyruvate induced apoptosis in a number of different murine breast cancer cell lines, including the highly metastatic 4T1 line. The dying tumor cells stimulated immature dendritic cells (DCs) of the immortal JAWS II cell line to produce high levels of the pro-inflammatory cytokine IL-12, and increased their expression of key co-stimulatory molecules CD80 and CD86. The activated dendritic cells showed increased uptake of fragments from dying tumor cells that correlated with the increased levels of calreticulin on the surface and release of high group motility box 1 (HMGB1) of the latter following 3-BP treatment. Additionally, the anti-phagocytic signal CD47 present on breast cancer cells was reduced by treatment with 3-bromopyruvate when compared to the levels on untreated 4T1 cells. 3-BP treated breast cancer cells were able to activate dendritic cells through TLR4 signaling. Signaling was dependent on both the expression of surface calreticulin and on the extracellular release of high mobility group box 1 protein (HMGB1) during the process of immunogenic cell death. Killing by 3-BP was compared to mitoxantrone and doxorubicin, among the few chemotherapeutics that induce immunogenic cell death. 3-BP killing was likewise compared to camptothecin, a compound that fails to induce immunogenic cell death. Importantly, 3-BP did not markedly decrease the levels of the key peptide presenting molecule MHC I on DCs that were co-cultivated with dying tumor cells. Treatment of the highly aggressive triple negative BT-20 human breast cancer cell line with 3-BP also induced an immunogenic cell death, activating human dendritic cells in vitro.
Show less
Date Issued: 2017
PURL: http://purl.flvc.org/fau/fd/FA00004834
Subject Headings: Apoptosis., Cellular signal transduction., Cell death., Breast--Cancer--Treatment., Carrier proteins., Cancer--Molecular aspects., Biological interfaces.
Format: Document (PDF)

Title: Therapeutic Options for the Treatment of Breast Cancer: Using Cytoreg and Genistein Isoflavone.
Creator: Johnson, Michelle M., Kumi-Diaka, James, Florida Atlantic University, Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description: In spite the heavy investments in therapeutic research breast cancer still impacts the lives of women globally. The projected incidence of new cases in USA for 2008 is 67,770, with estimated 40,480 deaths. In this study, we investigated the therapeutic efficacy of Cytoreg®-genistein combination treatment on MCF-7 human breast cancer cells. MCF-7 cells were treated with genistein and Cytoreg® single and combination treatments for 24- 48hr; and the chemosensitivity assessed using bioassays:...
Show moreIn spite the heavy investments in therapeutic research breast cancer still impacts the lives of women globally. The projected incidence of new cases in USA for 2008 is 67,770, with estimated 40,480 deaths. In this study, we investigated the therapeutic efficacy of Cytoreg®-genistein combination treatment on MCF-7 human breast cancer cells. MCF-7 cells were treated with genistein and Cytoreg® single and combination treatments for 24- 48hr; and the chemosensitivity assessed using bioassays: Trypan Blue and MTT for cell viability; Ethidium bromide/Rhodamine 123 to assess apoptosis induction; F AM PolyCaspase binding assay for mechanism of action. The overall data indicated dose- and timedependent cell death in the MCF-cells and that apoptosis was the major means of treatmentinduced growth inhibition. There was evidence of Cytoreg®-induced autophagy in the cells. The overall findings indicated that genistein-Cytoreg® combination was more efficacious than either genistein or Cytoreg® alone. Cytoreg® enhanced the phytosensitivity of MCF-7 cells to genistein isoflavone.
Show less
Date Issued: 2008
PURL: http://purl.flvc.org/fau/fd/FA00000777
Subject Headings: Breast--Cancer--Treatment, Phytochemicals--Physiological effect, Apoptosis--Molecular aspects, Phytoestrogens--Health aspects, Outcome assessment (Medical care)
Format: Document (PDF)

FAU Theses and Dissertations (13)	+ -
FAU Graduate Student Research (1)	+ -

Breast--Cancer--Treatment (6)	+ -
Apoptosis--Molecular aspects (3)	+ -
Breast--Cancer--Treatment. (3)	+ -
Phytochemicals--Physiological effect (3)	+ -
Breast (2)	+ -

Breast--Cancer--Molecular aspects (2)	+ -
Cancer (2)	+ -
Cancer--Molecular aspects. (2)	+ -
Treatment (2)	+ -
Women--Diseases--Alternative treatment (2)	+ -
Antineoplastic agents -- Development (1)	+ -
Antioxidants (1)	+ -
Apoptosis. (1)	+ -
Biological interfaces. (1)	+ -
Biological response modifiers. (1)	+ -
Breast -- Cancer -- Treatment (1)	+ -
Breast--Cancer (1)	+ -
Breast--Cancer--Radiotherapy. (1)	+ -
Breast -- Cancer -- Treatment (1)	+ -
Cancer -- Genetic aspects (1)	+ -
Cancer--Immunological aspects. (1)	+ -
Cancer--Treatment (1)	+ -
Cancer -- Radiation therapy (1)	+ -
Carrier proteins. (1)	+ -
Cell death. (1)	+ -
Cellular signal transduction. (1)	+ -
Chemoprevention (1)	+ -
DNA mircroarrays (1)	+ -
Deoxyglucose (1)	+ -
Estimation theory (1)	+ -

Electronic Thesis or Dissertation (13)	+ -
abstract (1)	+ -

Florida Atlantic University (11)	+ -
Charles E. Schmidt College of Science (10)	+ -
Department of Biological Sciences (6)	+ -
Department of Physics (4)	+ -
Hartmann, James X. (4)	+ -

Search In

Sort Results By:

Narrow results by:

Collection

Topical Subject

Genre

Type of Resource

Language

Creator

Format

Owner